Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Eugene Braunwald, M.D.

Co-Author

This page shows the publications co-authored by Eugene Braunwald and Robert Giugliano.
Connection Strength

22.358
  1. Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo: Analysis From IMPROVE-IT. JACC CardioOncol. 2020 Sep; 2(3):385-396.
    View in: PubMed
    Score: 0.895
  2. Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial. JAMA Cardiol. 2017 05 01; 2(5):547-555.
    View in: PubMed
    Score: 0.708
  3. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. Am J Med. 2016 Aug; 129(8):850-857.e2.
    View in: PubMed
    Score: 0.655
  4. The year in acute coronary syndrome. J Am Coll Cardiol. 2014 Jan 28; 63(3):201-14.
    View in: PubMed
    Score: 0.557
  5. The year in non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol. 2012 Nov 20; 60(21):2127-39.
    View in: PubMed
    Score: 0.518
  6. The year in non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol. 2011 Nov 22; 58(22):2342-54.
    View in: PubMed
    Score: 0.486
  7. The year in non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol. 2010 Dec 14; 56(25):2126-38.
    View in: PubMed
    Score: 0.455
  8. Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial. Eur Heart J. 2010 Sep; 31(17):2103-10.
    View in: PubMed
    Score: 0.435
  9. The year in non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol. 2009 Oct 13; 54(16):1544-55.
    View in: PubMed
    Score: 0.420
  10. The year in non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol. 2008 Sep 23; 52(13):1095-103.
    View in: PubMed
    Score: 0.390
  11. The year in non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol. 2007 Oct 02; 50(14):1386-95.
    View in: PubMed
    Score: 0.363
  12. The year in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2006 Jul 18; 48(2):386-95.
    View in: PubMed
    Score: 0.334
  13. The year in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2005 Sep 06; 46(5):906-19.
    View in: PubMed
    Score: 0.316
  14. Baseline troponin in acute coronary syndromes managed invasively. Am J Med. 2004 Dec 15; 117(12):963-5.
    View in: PubMed
    Score: 0.300
  15. Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. Am J Cardiol. 2004 Jun 01; 93(11):1362-7, A5-6.
    View in: PubMed
    Score: 0.289
  16. Improving antithrombotic treatment in patients after myocardial infarction. Lancet. 2003 Sep 06; 362(9386):757.
    View in: PubMed
    Score: 0.275
  17. Reply: Analyzing IMPROVE-IT Beyond LDL Cholesterol. J Am Coll Cardiol. 2022 02 01; 79(4):e153.
    View in: PubMed
    Score: 0.246
  18. Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups. Am Heart J. 2022 May; 247:24-32.
    View in: PubMed
    Score: 0.245
  19. Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. J Am Coll Cardiol. 2021 10 12; 78(15):1499-1507.
    View in: PubMed
    Score: 0.241
  20. Reply: Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration? J Am Coll Cardiol. 2021 06 29; 77(25):3232-3233.
    View in: PubMed
    Score: 0.236
  21. Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants: meta-analysis of eight outcomes in 58 634 patients across four randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. 2021 04 09; 7(FI1):f40-f49.
    View in: PubMed
    Score: 0.233
  22. Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation. J Am Coll Cardiol. 2021 03 09; 77(9):1197-1207.
    View in: PubMed
    Score: 0.231
  23. Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial. Thromb Haemost. 2021 Feb; 121(2):140-149.
    View in: PubMed
    Score: 0.224
  24. First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials. Am Heart J. 2000 Jul; 140(1):81-93.
    View in: PubMed
    Score: 0.220
  25. Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial. Int J Cardiol. 2020 04 01; 304:185-191.
    View in: PubMed
    Score: 0.214
  26. Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial. Circulation. 2019 11 26; 140(22):1792-1801.
    View in: PubMed
    Score: 0.210
  27. Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial. Hypertension. 2019 09; 74(3):597-605.
    View in: PubMed
    Score: 0.207
  28. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease. J Am Coll Cardiol. 2019 07 16; 74(2):179-189.
    View in: PubMed
    Score: 0.206
  29. Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2019 05 14; 40(19):1518-1527.
    View in: PubMed
    Score: 0.204
  30. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2019 05 14; 40(19):1541-1550.
    View in: PubMed
    Score: 0.204
  31. Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial. Europace. 2019 Feb 01; 21(2):306-312.
    View in: PubMed
    Score: 0.200
  32. Modes and timing of death in 66?252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. Eur Heart J. 2018 11 07; 39(42):3810-3820.
    View in: PubMed
    Score: 0.197
  33. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol. 2018 12; 6(12):934-943.
    View in: PubMed
    Score: 0.196
  34. Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial. Circulation. 2018 10 30; 138(18):1963-1973.
    View in: PubMed
    Score: 0.196
  35. Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 Trial. J Am Coll Cardiol. 2018 09 25; 72(13):1466-1475.
    View in: PubMed
    Score: 0.195
  36. Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 Trial. J Am Heart Assoc. 2018 08 21; 7(16):e008987.
    View in: PubMed
    Score: 0.194
  37. Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48. Eur Heart J Acute Cardiovasc Care. 2019 Mar; 8(2):176-185.
    View in: PubMed
    Score: 0.193
  38. Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation. 2018 06 12; 137(24):2662-2663.
    View in: PubMed
    Score: 0.191
  39. Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial. Thromb Haemost. 2018 06; 118(6):1001-1008.
    View in: PubMed
    Score: 0.190
  40. Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction). Circ Cardiovasc Qual Outcomes. 2018 05; 11(5):e003998.
    View in: PubMed
    Score: 0.190
  41. Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial. Int J Cardiol. 2018 04 15; 257:102-107.
    View in: PubMed
    Score: 0.187
  42. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018 04 10; 137(15):1571-1582.
    View in: PubMed
    Score: 0.185
  43. Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). J Am Heart Assoc. 2017 Nov 18; 6(11).
    View in: PubMed
    Score: 0.184
  44. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2017 Dec 19; 136(25):2440-2450.
    View in: PubMed
    Score: 0.182
  45. Reply: Ezetimibe, Risk Stratification, and Secondary Prevention. J Am Coll Cardiol. 2017 08 29; 70(9):1200.
    View in: PubMed
    Score: 0.181
  46. Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc. 2017 Jun 30; 6(7).
    View in: PubMed
    Score: 0.179
  47. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial. J Am Coll Cardiol. 2017 Mar 21; 69(11):1372-1382.
    View in: PubMed
    Score: 0.176
  48. A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. Eur Heart J. 2017 Mar 21; 38(12):888-896.
    View in: PubMed
    Score: 0.176
  49. Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. J Am Coll Cardiol. 2017 Feb 28; 69(8):911-921.
    View in: PubMed
    Score: 0.175
  50. Reexamination of the Thrombin Hypothesis: What We Have Learned from TIMI 9B and GUSTO IIb. J Thromb Thrombolysis. 1997; 4(3/4):321-323.
    View in: PubMed
    Score: 0.173
  51. On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). Am Heart J. 2016 Dec; 182:89-96.
    View in: PubMed
    Score: 0.170
  52. Updates on Acute Coronary Syndrome: A Review. JAMA Cardiol. 2016 09 01; 1(6):718-30.
    View in: PubMed
    Score: 0.169
  53. Reply: Personalize and Optimize Lipid-Lowering Therapies. J Am Coll Cardiol. 2016 07 19; 68(3):326.
    View in: PubMed
    Score: 0.168
  54. Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc. 2016 07 08; 5(7).
    View in: PubMed
    Score: 0.167
  55. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation. 2016 Jul 05; 134(1):24-36.
    View in: PubMed
    Score: 0.167
  56. Reply: Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease: Is it Useful? J Am Coll Cardiol. 2016 06 28; 67(25):3025-6.
    View in: PubMed
    Score: 0.167
  57. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48. Eur J Heart Fail. 2016 09; 18(9):1153-61.
    View in: PubMed
    Score: 0.167
  58. Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT". Circulation. 2016 Mar 29; 133(13):e463.
    View in: PubMed
    Score: 0.164
  59. Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial. J Am Heart Assoc. 2016 Feb 23; 5(2).
    View in: PubMed
    Score: 0.163
  60. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. J Am Coll Cardiol. 2016 Feb 02; 67(4):353-361.
    View in: PubMed
    Score: 0.162
  61. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial. Am Heart J. 2016 Feb; 172:144-51.
    View in: PubMed
    Score: 0.160
  62. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation. 2015 Sep 29; 132(13):1224-33.
    View in: PubMed
    Score: 0.158
  63. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48. Stroke. 2014 Aug; 45(8):2372-8.
    View in: PubMed
    Score: 0.145
  64. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28; 369(22):2093-104.
    View in: PubMed
    Score: 0.139
  65. Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. J Cardiovasc Pharmacol Ther. 2013 Nov; 18(6):555-9.
    View in: PubMed
    Score: 0.138
  66. Circadian variation in patient characteristics and outcomes in ST-segment elevation myocardial infarction. Chronobiol Int. 2012 Dec; 29(10):1390-6.
    View in: PubMed
    Score: 0.130
  67. Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation. 2011 Jun 14; 123(23):2681-9.
    View in: PubMed
    Score: 0.117
  68. Prior aspirin use and outcomes in acute coronary syndromes. J Am Coll Cardiol. 2010 Oct 19; 56(17):1376-85.
    View in: PubMed
    Score: 0.113
  69. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010 Oct; 160(4):635-41.
    View in: PubMed
    Score: 0.112
  70. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am Heart J. 2010 May; 159(5):705-9.
    View in: PubMed
    Score: 0.108
  71. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009 May 21; 360(21):2176-90.
    View in: PubMed
    Score: 0.101
  72. Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trial. Am Heart J. 2009 Apr; 157(4):673-9.e1.
    View in: PubMed
    Score: 0.100
  73. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis. J Am Coll Cardiol. 2008 Sep 09; 52(11):914-20.
    View in: PubMed
    Score: 0.097
  74. A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study. Eur Heart J. 2007 Sep; 28(17):2070-6.
    View in: PubMed
    Score: 0.089
  75. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. J Am Coll Cardiol. 2007 Jun 26; 49(25):2398-407.
    View in: PubMed
    Score: 0.089
  76. The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. J Am Coll Cardiol. 2006 Jul 04; 48(1):37-42.
    View in: PubMed
    Score: 0.083
  77. Poor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: impact of age (a meta-analysis of a decade of trials). J Thromb Thrombolysis. 2006 Apr; 21(2):119-29.
    View in: PubMed
    Score: 0.082
  78. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale. Am Heart J. 2005 Jun; 149(6):994-1002.
    View in: PubMed
    Score: 0.077
  79. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation. 2005 Apr 26; 111(16):2042-9.
    View in: PubMed
    Score: 0.077
  80. 2004 ACC/AHA guideline for the management of patients with STEMI: the implications for clinicians. Nat Clin Pract Cardiovasc Med. 2005 Mar; 2(3):114-5.
    View in: PubMed
    Score: 0.076
  81. Severity of heart failure, treatments, and outcomes after fibrinolysis in patients with ST-elevation myocardial infarction. Eur Heart J. 2004 Oct; 25(19):1702-10.
    View in: PubMed
    Score: 0.074
  82. Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Aug 18; 44(4):783-9.
    View in: PubMed
    Score: 0.073
  83. Angiographic perfusion score: an angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction. Am Heart J. 2004 Aug; 148(2):336-40.
    View in: PubMed
    Score: 0.073
  84. The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies. Eur Heart J. 2004 Jul; 25(13):1139-45.
    View in: PubMed
    Score: 0.073
  85. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. Circulation. 2004 Feb 10; 109(5):580-6.
    View in: PubMed
    Score: 0.071
  86. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial. Circulation. 2004 Feb 24; 109(7):874-80.
    View in: PubMed
    Score: 0.071
  87. Selecting the best reperfusion strategy in ST-elevation myocardial infarction: it's all a matter of time. Circulation. 2003 Dec 09; 108(23):2828-30.
    View in: PubMed
    Score: 0.070
  88. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. J Am Coll Cardiol. 2003 Apr 16; 41(8):1251-60.
    View in: PubMed
    Score: 0.067
  89. Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial. J Am Coll Cardiol. 2002 Jul 03; 40(1):71-7.
    View in: PubMed
    Score: 0.063
  90. Identification of patients at high risk for death and cardiac ischemic events after hospital discharge. Am Heart J. 2002 Jun; 143(6):966-70.
    View in: PubMed
    Score: 0.063
  91. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. JAMA Cardiol. 2022 Mar 01; 7(3):250-256.
    View in: PubMed
    Score: 0.062
  92. Cardiovascular Events and Long-Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE-IT. J Am Heart Assoc. 2022 02 15; 11(4):e022733.
    View in: PubMed
    Score: 0.062
  93. Ischemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full and half-dose Edoxaban vs. Warfarin: insights from ENGAGE AF-TIMI 48. Eur Heart J Cardiovasc Pharmacother. 2021 Dec 28.
    View in: PubMed
    Score: 0.061
  94. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet. 2001 Nov 10; 358(9293):1571-5.
    View in: PubMed
    Score: 0.061
  95. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA. 2001 Sep 19; 286(11):1356-9.
    View in: PubMed
    Score: 0.060
  96. Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-II. Eur Heart J. 2001 Sep; 22(18):1702-15.
    View in: PubMed
    Score: 0.060
  97. A Targeted Proteomic Approach Identifies Novel Biomarkers of Arterial Thromboembolic Risk in ENGAGE AF-TIMI 48. J Am Coll Cardiol. 2021 08 10; 78(6):634-636.
    View in: PubMed
    Score: 0.060
  98. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. Am Heart J. 2001 May; 141(5):742-50.
    View in: PubMed
    Score: 0.058
  99. Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2021 05 01; 42(17):1698-1706.
    View in: PubMed
    Score: 0.058
  100. Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. Circulation. 2021 02 16; 143(7):685-695.
    View in: PubMed
    Score: 0.058
  101. Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. Circulation. 2021 02 16; 143(7):673-684.
    View in: PubMed
    Score: 0.058
  102. Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. Circ Genom Precis Med. 2021 02; 14(1):e003006.
    View in: PubMed
    Score: 0.057
  103. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial. J Clin Neurosci. 2021 Apr; 86:294-300.
    View in: PubMed
    Score: 0.057
  104. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Eur Heart J. 2000 Dec; 21(23):1944-53.
    View in: PubMed
    Score: 0.057
  105. Comparison of a 60- versus 90-minute determination of ST-segment resolution after thrombolytic therapy for acute myocardial infarction. In TIME-II Investigators. Intravenous nPA for Treatment of Infarcting Myocardium Early-II. Am J Cardiol. 2000 Dec 01; 86(11):1235-7, A5.
    View in: PubMed
    Score: 0.057
  106. Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation. 2021 02 02; 143(5):470-478.
    View in: PubMed
    Score: 0.057
  107. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020 11 21; 396(10263):1637-1643.
    View in: PubMed
    Score: 0.057
  108. Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial. Circ Cardiovasc Qual Outcomes. 2020 11; 13(11):e006511.
    View in: PubMed
    Score: 0.056
  109. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000 Oct 24; 102(17):2031-7.
    View in: PubMed
    Score: 0.056
  110. Very early risk stratification after thrombolytic therapy with a bedside myoglobin assay and the 12-lead electrocardiogram. Am Heart J. 2000 Sep; 140(3):373-8.
    View in: PubMed
    Score: 0.056
  111. ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 investigators. Am J Cardiol. 2000 Feb 01; 85(3):299-304.
    View in: PubMed
    Score: 0.054
  112. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. Circulation. 2000 Jan 25; 101(3):239-43.
    View in: PubMed
    Score: 0.053
  113. Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. J Am Coll Cardiol. 2019 12 17; 74(24):3013-3022.
    View in: PubMed
    Score: 0.053
  114. Left atrial structure and function and the risk of death or heart failure in atrial fibrillation. Eur J Heart Fail. 2019 12; 21(12):1571-1579.
    View in: PubMed
    Score: 0.053
  115. Determinants of coronary blood flow after thrombolytic administration. TIMI Study Group. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1999 Nov 01; 34(5):1403-12.
    View in: PubMed
    Score: 0.053
  116. Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. The TIMI Study Group. Thrombolysis in myocardial infarction. J Am Coll Cardiol. 1999 Oct; 34(4):974-82.
    View in: PubMed
    Score: 0.052
  117. Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2019 09 01; 4(9):846-854.
    View in: PubMed
    Score: 0.052
  118. Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial. J Am Coll Cardiol. 2019 08 27; 74(8):1057-1068.
    View in: PubMed
    Score: 0.052
  119. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation. 1999 Jun 01; 99(21):2720-32.
    View in: PubMed
    Score: 0.051
  120. Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48. Circulation. 2019 02 05; 139(6):760-771.
    View in: PubMed
    Score: 0.050
  121. Medication Discontinuation in the IMPROVE-IT Trial. Circ Cardiovasc Qual Outcomes. 2019 01; 12(1):e005041.
    View in: PubMed
    Score: 0.050
  122. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation. 1998 Dec 22-29; 98(25):2805-14.
    View in: PubMed
    Score: 0.049
  123. Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2018 05 14; 11(9):856-864.
    View in: PubMed
    Score: 0.048
  124. Competing Risks of Cardiovascular Versus Noncardiovascular Death During Long-Term Follow-Up After Acute Coronary Syndromes. J Am Heart Assoc. 2017 Sep 18; 6(9).
    View in: PubMed
    Score: 0.045
  125. Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circ Cardiovasc Qual Outcomes. 2017 05; 10(5).
    View in: PubMed
    Score: 0.044
  126. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Circ Arrhythm Electrophysiol. 2017 01; 10(1).
    View in: PubMed
    Score: 0.043
  127. Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation: A Subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial. JAMA Cardiol. 2016 Dec 01; 1(9):999-1006.
    View in: PubMed
    Score: 0.043
  128. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016 Sep 27; 316(12):1289-97.
    View in: PubMed
    Score: 0.042
  129. Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis. J Am Coll Cardiol. 2016 09 13; 68(11):1169-1178.
    View in: PubMed
    Score: 0.042
  130. The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. Eur Heart J. 2016 Dec 21; 37(48):3576-3584.
    View in: PubMed
    Score: 0.042
  131. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Stroke. 2016 08; 47(8):2075-82.
    View in: PubMed
    Score: 0.042
  132. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc. 2016 05 20; 5(5).
    View in: PubMed
    Score: 0.041
  133. The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy. J Am Soc Echocardiogr. 2016 06; 29(6):537-44.
    View in: PubMed
    Score: 0.041
  134. Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial. Am Heart J. 2015 Oct; 170(4):669-74.
    View in: PubMed
    Score: 0.039
  135. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015 Jun 18; 372(25):2387-97.
    View in: PubMed
    Score: 0.039
  136. Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2015 Sep 01; 36(33):2239-45.
    View in: PubMed
    Score: 0.039
  137. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015 Jun 06; 385(9984):2280-7.
    View in: PubMed
    Score: 0.038
  138. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015 Jun 06; 385(9984):2288-95.
    View in: PubMed
    Score: 0.038
  139. Prognostic implications of low level cardiac troponin elevation using high-sensitivity cardiac troponin T. Clin Cardiol. 2015 Apr; 38(4):230-5.
    View in: PubMed
    Score: 0.038
  140. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†. Eur Heart J. 2015 Jun 14; 36(23):1470-7.
    View in: PubMed
    Score: 0.038
  141. Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol. 2014 Aug 12; 64(6):576-84.
    View in: PubMed
    Score: 0.037
  142. New oral anticoagulants in patients with atrial fibrillation - Authors'reply. Lancet. 2014 Jul 05; 384(9937):25-6.
    View in: PubMed
    Score: 0.036
  143. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am Heart J. 2014 Aug; 168(2):205-12.e1.
    View in: PubMed
    Score: 0.036
  144. Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial). Am J Cardiol. 2014 Apr 15; 113(8):1297-305.
    View in: PubMed
    Score: 0.035
  145. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014 Mar 15; 383(9921):955-62.
    View in: PubMed
    Score: 0.035
  146. Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. Eur Heart J. 2014 Jun 07; 35(22):1457-65.
    View in: PubMed
    Score: 0.035
  147. Prognostic performance of a high-sensitivity cardiac troponin I assay in patients with non-ST-elevation acute coronary syndrome. Clin Chem. 2014 Jan; 60(1):158-64.
    View in: PubMed
    Score: 0.034
  148. Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends. J Am Coll Cardiol. 2013 Jul 16; 62(3):242-251.
    View in: PubMed
    Score: 0.034
  149. Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes. Int J Cardiol. 2013 Oct 03; 168(3):2510-7.
    View in: PubMed
    Score: 0.033
  150. Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. Am Heart J. 2013 Jun; 165(6):918-925.e2.
    View in: PubMed
    Score: 0.033
  151. Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. JACC Cardiovasc Interv. 2012 Sep; 5(9):927-35.
    View in: PubMed
    Score: 0.032
  152. Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial. Int J Cardiol. 2013 Sep 10; 167(6):2580-7.
    View in: PubMed
    Score: 0.032
  153. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials. Circ Cardiovasc Qual Outcomes. 2011 Jul; 4(4):448-58.
    View in: PubMed
    Score: 0.030
  154. Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial. Circulation. 2011 Feb 22; 123(7):722-30.
    View in: PubMed
    Score: 0.029
  155. Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world. Int J Cardiol. 2012 Mar 22; 155(3):424-9.
    View in: PubMed
    Score: 0.028
  156. Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy. JACC Cardiovasc Interv. 2010 Aug; 3(8):806-11.
    View in: PubMed
    Score: 0.028
  157. One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 trial. Eur Heart J. 2010 Sep; 31(17):2097-102.
    View in: PubMed
    Score: 0.027
  158. Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction. Am Heart J. 2010 Jan; 159(1):55-62.
    View in: PubMed
    Score: 0.027
  159. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008 Nov; 156(5):826-32.
    View in: PubMed
    Score: 0.024
  160. The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromes. Int J Cardiol. 2008 Dec 17; 131(1):105-12.
    View in: PubMed
    Score: 0.023
  161. Association of a history of systemic hypertension with mortality, thrombotic, and bleeding complications following non-ST-segment elevation acute coronary syndrome. J Clin Hypertens (Greenwich). 2006 May; 8(5):315-22.
    View in: PubMed
    Score: 0.021
  162. U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2005 Jul 05; 46(1):178-80.
    View in: PubMed
    Score: 0.019
  163. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med. 2005 Apr 21; 352(16):1646-54.
    View in: PubMed
    Score: 0.019
  164. Association of culprit lesion calcium with angiographic and clinical outcomes in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy. Am J Cardiol. 2005 Feb 01; 95(3):337-42.
    View in: PubMed
    Score: 0.019
  165. Association of a negative residual stenosis following rescue/adjunctive percutaneous coronary intervention with impaired myocardial perfusion and adverse outcomes among ST-segment elevation myocardial infarction patients. J Am Coll Cardiol. 2005 Feb 01; 45(3):357-62.
    View in: PubMed
    Score: 0.019
  166. Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2005 Jan 18; 45(2):321-3.
    View in: PubMed
    Score: 0.019
  167. Relation of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction. Am J Cardiol. 2005 Jan 15; 95(2):224-7.
    View in: PubMed
    Score: 0.019
  168. Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. Am J Cardiol. 2004 Dec 01; 94(11):1406-10.
    View in: PubMed
    Score: 0.019
  169. Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. Am J Cardiol. 2004 Nov 01; 94(9):1113-7.
    View in: PubMed
    Score: 0.019
  170. Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. Eur Heart J. 2004 Nov; 25(22):1998-2005.
    View in: PubMed
    Score: 0.019
  171. Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Sep 01; 44(5):980-7.
    View in: PubMed
    Score: 0.018
  172. Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy. Circulation. 2004 Aug 10; 110(6):679-84.
    View in: PubMed
    Score: 0.018
  173. Effect of rescue or adjunctive percutaneous coronary intervention of the culprit artery after fibrinolytic administration on epicardial flow in nonculprit arteries. Am J Cardiol. 2004 Jul 15; 94(2):178-81.
    View in: PubMed
    Score: 0.018
  174. Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction. Am Heart J. 2004 May; 147(5):847-52.
    View in: PubMed
    Score: 0.018
  175. Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. J Am Coll Cardiol. 2004 Apr 07; 43(7):1170-6.
    View in: PubMed
    Score: 0.018
  176. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol. 2003 Nov 05; 42(9):1535-43.
    View in: PubMed
    Score: 0.017
  177. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol. 2003 Jul 02; 42(1):7-16.
    View in: PubMed
    Score: 0.017
  178. Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction; insights from TIMI 14 and InTIME-II. Eur Heart J. 2002 Jun; 23(12):928-33.
    View in: PubMed
    Score: 0.016
  179. Availability of on-site catheterization and clinical outcomes in patients receiving fibrinolysis for ST-elevation myocardial infarction. Eur Heart J. 2001 Nov; 22(22):2104-15.
    View in: PubMed
    Score: 0.015
  180. Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience). Am J Cardiol. 2001 Oct 15; 88(8):831-6.
    View in: PubMed
    Score: 0.015
  181. Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy. Am J Cardiol. 2001 Aug 15; 88(4):353-8.
    View in: PubMed
    Score: 0.015
  182. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14. Circulation. 2000 Jun 13; 101(23):2690-5.
    View in: PubMed
    Score: 0.014
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.